Treatment Action Group

An Activist’s Guide to Shorter Treatment for Drug-Resistant TB

This new resource lays out what activists need to know about the new drug-resistant TB treatment regimens, and equips them with actions they can take and arguments they can use to advocate for access to those regimens.

Read More →

Activism delivers unprecedented victories in TB testing and treatment access

Historic price reductions will allow millions more people to receive TB prevention, treatment and testing.

Read More →

TAG's 2023 Pipeline Report: TB vaccines

Treatment Action Group launches the first TB chapter of its 2023 Pipeline Report.

Read More →

TAG condemns GSK actions surrounding potential TB vaccine revealed by bombshell ProPublica report

The report portrays how GSK’s financial interests have – and will likely continue to – set back progress against the world’s deadliest infectious disease lays bare just how egregiously large pharmaceutical companies bilk the global public, and makes an urgent case for government and philanthropic funders to take action and demand better.

Read More →

Nearly all countries “far off track” of meeting TB research targets despite publicly reaffirming commitments at UN

A sobering new analysis from Treatment Action Group shows that governments failed to meet previous commitments to fund TB research.

Read More →

At this week’s UN General Assembly High-Level Meeting on TB, the 1/4/6×24 Campaign calls on political leaders to take urgent action for equitable access to shorter, safer TB regimens

Ahead of the UN General Assembly High-Level Meeting on TB, the 1/4/6×24 Campaign is sounding the alarm that the political declaration commits neither the funding nor the actions needed to expand access to the best-available TB regimens and diagnostics.

Read More →

Information note: New fair share funding targets for TB research 0.1% -> 0.15%

Treatment Action Group releases an updated Information note providing details on the new 0.15% fair share funding targets for TB research.

Read More →

Open letter to Johnson & Johnson requesting clarification on the recent deal on generic bedaquiline supply

Advocates call for clarity on the terms of the Johnson & Johnson's deal with the Stop TB Partnership’s Global Drug Facility to supply generic bedaquiline.

Read More →

An Activist’s Protocol Review Toolkit

A toolkit, developed by Treatment Action Group, is designed to facilitate community participation in the development and review of clinical trials protocols.

Read More →

TAG webinar: TB vaccine development: The next chapter starts now - webinar materials now available online

Treatment Action Group (TAG) organized a webinar on 13 April 2023 providing an overview of the TB vaccine pipeline, based on TAG’s recent Tuberculosis Vaccines Pipeline Report, including the different candidates at different stages of research, and ongoing and upcoming studies that advocates should closely follow.

Read More →

Page 2 of 23 · Total posts: 10

←First 1 2 3 Last→